151 related articles for article (PubMed ID: 31378709)
1. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
Goody RS; Müller MP; Rauh D
Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
[TBL] [Abstract][Full Text] [Related]
2. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the guanine nucleotide exchange reaction of Ras GTPase--evidence for a GTP/GDP displacement model.
Zhang B; Zhang Y; Shacter E; Zheng Y
Biochemistry; 2005 Feb; 44(7):2566-76. PubMed ID: 15709769
[TBL] [Abstract][Full Text] [Related]
4. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
[TBL] [Abstract][Full Text] [Related]
5. Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.
Gentile DR; Rathinaswamy MK; Jenkins ML; Moss SM; Siempelkamp BD; Renslo AR; Burke JE; Shokat KM
Cell Chem Biol; 2017 Dec; 24(12):1455-1466.e14. PubMed ID: 29033317
[TBL] [Abstract][Full Text] [Related]
6. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
8. Differential dynamics of RAS isoforms in GDP- and GTP-bound states.
Kapoor A; Travesset A
Proteins; 2015 Jun; 83(6):1091-106. PubMed ID: 25846136
[TBL] [Abstract][Full Text] [Related]
9. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
10.
Pálfy G; Vida I; Perczel A
Biomol NMR Assign; 2020 Apr; 14(1):1-7. PubMed ID: 31468366
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional analysis of a mutant Ras protein that is insensitive to nitric oxide activation.
Mott HR; Carpenter JW; Campbell SL
Biochemistry; 1997 Mar; 36(12):3640-4. PubMed ID: 9132016
[TBL] [Abstract][Full Text] [Related]
12. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Ostrem JM; Peters U; Sos ML; Wells JA; Shokat KM
Nature; 2013 Nov; 503(7477):548-51. PubMed ID: 24256730
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule modulation of Ras signaling.
Spiegel J; Cromm PM; Zimmermann G; Grossmann TN; Waldmann H
Nat Chem Biol; 2014 Aug; 10(8):613-22. PubMed ID: 24929527
[TBL] [Abstract][Full Text] [Related]
14. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
15. Electrostatic control of GTP and GDP binding in the oncoprotein p21ras.
Muegge I; Schweins T; Langen R; Warshel A
Structure; 1996 Apr; 4(4):475-89. PubMed ID: 8740369
[TBL] [Abstract][Full Text] [Related]
16. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
17. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
19. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]